BACKGROUND: It is known that vitamin D has many functions besides involvement in calcium metabolism. It has recently been recognized that vitamin D deficiency is associated with mortality, especially in cardiovascular disease (CVD). Vitamin D deficiency is common in end-stage renal disease, but develops from the early stage of chronic kidney disease (CKD). So we investigated whether the serum level of the activated form of vitamin D (1,25-dihydroxyvitamin D) affected mortality in patients with CKD stages 3 and 4. METHODS: Between January 1, 1995, and June 30, 2006 we measured serum 1,25-dihydroxyvitamin D In 226 patients with CKD stages 3 and 4 and classified the results into two groups depending on whether the level was below (group I) or above (group II) 20 pg/ml. We ended the follow-up period on December 31, 2006. We compared all-cause and cardiovascular mortality between the two groups. We also examined predictors of mortality by using Cox proportional regression analysis. RESULTS: Two-hundred and twenty-six patients (67 men and 159 women, mean age 67.0) were registered in this study, and groups 1 and 2 comprised 84 and 142 patients, respectively. During the follow-up period 43 patients died. CVD was the major cause of death, followed by infectious disease. The Kaplan-Meier survival curve revealed that all-cause mortality was significantly higher in group I, but a significant difference between CVD mortality in the two groups was not demonstrated. By Cox proportional regression analysis, group I was related to all-cause mortality, but this was not proved to be an independent predictor. CONCLUSION: The results suggested that serum level of 1,25-dihydroxyvitamin D was associated with all-cause mortality in patients with CKD stages 3 and 4.
BACKGROUND: It is known that vitamin D has many functions besides involvement in calcium metabolism. It has recently been recognized that vitamin D deficiency is associated with mortality, especially in cardiovascular disease (CVD). Vitamin D deficiency is common in end-stage renal disease, but develops from the early stage of chronic kidney disease (CKD). So we investigated whether the serum level of the activated form of vitamin D (1,25-dihydroxyvitamin D) affected mortality in patients with CKD stages 3 and 4. METHODS: Between January 1, 1995, and June 30, 2006 we measured serum 1,25-dihydroxyvitamin D In 226 patients with CKD stages 3 and 4 and classified the results into two groups depending on whether the level was below (group I) or above (group II) 20 pg/ml. We ended the follow-up period on December 31, 2006. We compared all-cause and cardiovascular mortality between the two groups. We also examined predictors of mortality by using Cox proportional regression analysis. RESULTS: Two-hundred and twenty-six patients (67 men and 159 women, mean age 67.0) were registered in this study, and groups 1 and 2 comprised 84 and 142 patients, respectively. During the follow-up period 43 patients died. CVD was the major cause of death, followed by infectious disease. The Kaplan-Meier survival curve revealed that all-cause mortality was significantly higher in group I, but a significant difference between CVD mortality in the two groups was not demonstrated. By Cox proportional regression analysis, group I was related to all-cause mortality, but this was not proved to be an independent predictor. CONCLUSION: The results suggested that serum level of 1,25-dihydroxyvitamin D was associated with all-cause mortality in patients with CKD stages 3 and 4.
Authors: M R Haussler; G K Whitfield; C A Haussler; J C Hsieh; P D Thompson; S H Selznick; C E Dominguez; P W Jurutka Journal: J Bone Miner Res Date: 1998-03 Impact factor: 6.741
Authors: Simerjot K Jassal; Michel Chonchol; Denise von Mühlen; Gerard Smits; Elizabeth Barrett-Connor Journal: Am J Med Date: 2010-10-01 Impact factor: 4.965
Authors: Charles Ginsberg; Leila R Zelnick; Geoffrey A Block; Glenn M Chertow; Michel Chonchol; Andrew Hoofnagle; Bryan Kestenbaum; Ian H de Boer Journal: Nephrol Dial Transplant Date: 2020-04-01 Impact factor: 5.992
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: Am J Kidney Dis Date: 2012-05-22 Impact factor: 8.860
Authors: William G Petchey; Erin J Howden; David W Johnson; Carmel M Hawley; Thomas Marwick; Nicole M Isbel Journal: Clin J Am Soc Nephrol Date: 2010-12-16 Impact factor: 8.237
Authors: Daniela Veit Barreto; Fellype Carvalho Barreto; Sophie Liabeuf; Mohammed Temmar; Francis Boitte; Gabriel Choukroun; Albert Fournier; Ziad A Massy Journal: Clin J Am Soc Nephrol Date: 2009-05-14 Impact factor: 8.237
Authors: William G Petchey; Ingrid J Hickman; Emma Duncan; Johannes B Prins; Carmel M Hawley; David W Johnson; Katherine Barraclough; Nicole M Isbel Journal: BMC Nephrol Date: 2009-12-10 Impact factor: 2.388